Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer

PURPOSE: Adding antiangiogenic therapy to standard chemotherapy has improved response rates and progression-free survival in metastatic breast cancer (BC) patients. This phase II study evaluated cardiac safety of bevacizumab with/without trastuzumab with two docetaxel-based regimens in early BC. MET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hurvitz, Sara A, Bosserman, Linda D, Chan, David, Hagenstad, Christopher T, Kass, Frederick C, Smith, Frederick P, Rodriguez, Gladys I, Childs, Barrett H, Slamon, Dennis J
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2014
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4031367/
https://ncbi.nlm.nih.gov/pubmed/24860718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2193-1801-3-244
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados